Gabapentin Capsule
Product Images NDC 42806-510

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 42806-510). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Epic Pharma, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Cockcroft Gault Equation

A formula for creatinine clearance (CLCr) calculation is shown, involving age, weight, serum creatinine, and a gender adjustment factor for female patients. It is a mathematical text panel related to pharmacokinetic considerations.*

FDA Label Image

Figure 1

A line graph showing mean pain scores over 8 weeks comparing Gabapentin 3600 mg/day and placebo. The x-axis represents weeks with baseline and 8 weeks labeled, and the y-axis shows mean pain scores from 0 to 10. The graph indicates a 4-week dose titration period followed by a 4-week fixed dose period. Gabapentin shows a decreasing pain score trend, while placebo remains relatively constant.*

FDA Label Image

Figure 2

A line graph depicting mean pain scores over a 7-week period comparing placebo and two dosing levels of gabapentin (1800 mg/day and 2400 mg/day). The x-axis represents weeks with a 3-week dose titration period followed by a 4-week fixed dose period. The y-axis shows mean pain scores ranging from 0 to 10. Both gabapentin groups show a decrease in pain score over time, while the placebo group remains relatively higher and stable.*

FDA Label Image

Figure 3

A bar chart comparing percentages between placebo (PBO) and Gabapentin (GBP) doses in two studies, labeled Study 1 and Study 2. Study 1 shows PBO at 12% and GBP 3600 at 29%. Study 2 shows PBO at 14%, GBP 1800 at 32%, and GBP 2400 at 34%, with statistical significance indicated by p-values less than 0.01 and 0.001.*

FDA Label Image

Figure 4

A scatter plot comparing the percentage difference at various daily doses (600 mg to 1800 mg) of a drug across three studies labeled a, b, and c. The x-axis represents daily dose in milligrams, and the y-axis represents difference in percentage, with study-specific markers distinguishing data points.*

FDA Label Image

Gabapentin 100mg 30ct

Gabapentin Capsules, USP 100 mg label from Epic Pharma, LLC. The label includes NDC 42806-509, manufacturer information, storage instructions (20 to 25°C), dosage form as capsules, and a 30-capsule count. It cautions to keep tightly closed and out of reach of children.*

FDA Label Image

Gabapentin 300mg 100ct

Gabapentin 300 mg Capsules, USP label from Epic Pharma, LLC. The packaging specifies oral capsules with 100 capsules per container, including storage instructions and a barcode. It highlights the NDC number 42806-510-01 and advises to keep medication out of children's reach.*

FDA Label Image

Gabapentin 400mg 1000ct

Gabapentin 400 mg Capsules, USP oral dosage form packaging label from Epic Pharma, LLC. The label indicates 1,000 capsules, prescription only, with storage instructions and a caution to keep out of children's reach. It includes the NDC 42806-511-10 and branding for Epic Pharma.*

FDA Label Image

Table-3 (Image 02)

A comparative table showing the incidence percentages of adverse reactions reported in patients treated with Gabapentin (n=336) versus placebo (n=227). Reactions are categorized by system, including Body as a Whole, Digestive System, Metabolic and Nutritional Disorders, Nervous System, Respiratory System, and Special Senses, with specific symptoms and their corresponding percentages listed for both groups.*

FDA Label Image

Table-6 (Image 03)

A data table summarizing two clinical studies of gabapentin showing study duration, gabapentin target doses in mg/day, and the number of patients receiving gabapentin versus placebo.*

FDA Label Image

Structural (Structural Formula)

Chemical structure of gabapentin showing a cyclohexane ring with an amino group and a carboxyl group attached, representing the molecular framework of the active ingredient gabapentin.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.